DrugPatentWatch Database Preview

Patent: 9,920,311

« Back to Dashboard

Summary for Patent: 9,920,311

Title:	PEGylated L-asparaginase
Abstract:	Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
Inventor(s):	Abribat; Thierry (Sainte Foy les Lyon, FR)
Assignee:	Jazz Pharmaceuticals II SAS (Lyons, FR)
Application Number:	14/819,305
Patent Claims:	see list of patent claims

Details for Patent 9,920,311

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Jazz Pharms Inc	ERWINAZE	asparaginase erwinia chrysanthemi	INJECTABLE; INJECTION	125359	001	2011-11-18		Jazz Pharmaceuticals II SAS (Lyons, FR)	2030-03-30	RX	Orphan	search
Merck	ELSPAR	asparaginase	VIAL	101063	001	1978-01-10		Jazz Pharmaceuticals II SAS (Lyons, FR)	2030-03-30	RX		search